The Evidence and Clinical Rationale for the Use of JAK Inhibitors in the Management of AD
DOI:
https://doi.org/10.58931/cait.2022.2s1148Abstract
Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases affecting 1 in 5 children and 1 in 10–20 adults. AD is characterized by clinical symptoms and signs of erythema, edema, excoriation, lichenification, xerosis, and in pediatric populations, oozing and weeping is more prevalent. Intense itch associated with AD can negatively impact sleep and quality of life. The consequences of sleep disturbance and fatigue may be underdiagnosed in this population. Atopic dermatitis has been associated with medical comorbidities that fall within type 2 inflammatory conditions (e.g., such as asthma, allergic rhinoconjunctivitis, and food allergies) as well as non-type-2 inflammatory conditions such as cardiometabolic disease, infections (both cutaneous and non-cutaneous), anxiety/depression, and autoimmune conditions such impetigo and alopecia aerata. AD has the strongest impairment of life expectancy outside of malignancy when it comes to dermatologic disease. While topical therapies such as topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), and phosphodiesterase 4 (PDE4) inhibitors are effective treatments for most patients with mild-to- moderate AD, more than 90% of those suffering from moderate-to-severe AD report significant unmet need along with the use of multiple therapeutic options, including off-label systemic medications which do not offer symptom control. Patients with refractory disease commonly receive acute courses oral corticosteroids, if not chronic treatment with systemic therapies, either off-label immunosuppressive agents e.g., methotrexate) or the immunomodulator dupilumab (a monoclonal antibody) targeting components of the inflammatory signature characterizing moderate-to-severe AD. In this paper we review and summarize the role and clinical application of an emerging class of systemic targeted therapy, namely the oral Janus kinase inhibitors (JAKi) in the treatment and management of moderate-to-severe AD.
References
Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62(2):151–61.
Renert-Yuval Y,Guttman-Yassky E. Systemic therapies in atopic dermatitis: the pipeline. Clin Dermatol. 2017;35(4):387–97.
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.
Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol 2019;80:390-401.
Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis 2016;27:50-8.
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol 2018;121:604-12.e3.
Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol 2019;123:144-51.
Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders. Clin Dermatol 2017;35:360-6.
Hay RJ, Johns NE, Williams HC, Bolliger IW, Dellavalle RP, Margolis DJ, Marks R, Naldi L,Weinstock MA, Wulf SK, Michaud C, JL Murray C, Naghavi M. The global burden of skin disease in 2010: An analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014; 134:1527-1534.
Eczema Society of Canada. Atopic Dermatitis Quality of Life Report – Moderate-to-Severe Disease. 2016/2017 Survey Results.
Bin L, Leung DY. Genetic and epigenetic studies of atopic dermatitis. Allergy Asthma ClinImmunol 2016;12:52.
Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. AllergolInt 2013;62:151-61.
Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol 2017;139:1723-34.
Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151-60.
Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T, et al. Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol 2020;145:215-28.
Renert-Yuval Y, Del Duca E, Pavel AB, Fang M, Lefferdink R, Wu J, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol 2021;148:148-63.
Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol 2017;139:S65-76.
Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:1344-54.
Noda S, Suárez-Fariñas M, Ungar BA, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254–1264.
Weidinger S, et al. Nat Rev Dis Primers. 2018;4(1):1
Fania L, Moretta G, Antonelli F, Scala E, Abeni D, Albanesi C, Madonna S. Multiple Roles for Cytokines in Atopic Dermatitis: From Pathogenic Mediators to Endotype-Specific Biomarkers to Therapeutic Targets. Int J Mol Sci. 2022 Feb 28;23(5):2684.
Upadacitinib Product Monograph; accessed March 22nd, 2021; https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/RINVOQ_PM_EN.pdf
Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) thera peutic approaches. J Allergy Clin Immunol 2018;142:1375-90
Lei Bao, Huayi Zhang & Lawrence S Chan (2013) The involvement of the JAKSTAT signaling pathway in chronic inflammatory skin disease atopic dermatitis, JAK-STAT, 2:3, e24137.
Product monograph, DupixentTM, November 30 2017 ; https://pdf.hres.ca/dpd_pm/00042394.PDF
Simpson EL, Beiber T, et al. Two Phase 3 trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335-2348.
Blauvelt A, Teixeira HD, et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. JAMA Dermatol. 2021;157(9):1047-1055.
Blauvelt A, Ladisinski, et al. Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open Label Extension Trial. Abstract 2739. European Academy of Dermatology and Venereology. 2021 Sept.
Beiber T, Simpson EL, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384:1101-1112.
Shi VY, et al. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). Journal of the American Academy of Dermatology. 2022.
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis; https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-jade-dare-trial; accessed January 13th, 2022.
Castro M, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378:2486-2496.
Rabe, K, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med. 2018;378:2475-2485.
Bachert C, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: results from two multi centre, randomized, double blind, placebo-controlled parallel-group phase 3 trials. Lancet. 2019;394(10209)1638-165.
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800.
McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, Jeka S, Pacheco-Tena C, Wang X, Chen L, Zueger P, Liu J, Pangan AL, Behrens F. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1;384(13):1227-1239.
